Scholars Central

Conference abstractPublished 2019

Acetazolamide for severe early onset epileptic encephalopathy due to mutations in the KCNA2 gene

Authors: Khalid Hundallah

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Background: De novo loss or gain of function mutations in KCNA2 gene have been described in individuals with epileptic encephalopathy, ataxia or intellectual disability. Seizures are usually refractory to antiepileptic medications. Aim: Access the effect of acetazolamide on patients with early onset epileptic encephalopathy caused by KCNA2 gene mutation both clinically and electro-physiologically. Methods: We report a cohort of 11 patients with severe early onset epileptic encephalopathy carrying KCNA2 mutations. All had refractory seizures resistant to multiple antiepileptic drugs, significant developmental delay and slowing of EEG background. We started them on acetazolamide after antiepileptic medications failed. Pre and post therapy seizures burden and electroencephalography (EEG) studies were evaluated. Results: 9 of the 11 children (81%) showed a significant improvement both clinically and electro-physiologically and Acetazolamide is a potentially effective therapy in patients with early onset epileptic encephalopathy carrying KCNA2 mutations.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Neurology & Neurophysiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology & Neurophysiology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Khalid Hundallah”